Your session is about to expire
← Back to Search
Ertugliflozin for Heart Failure
Study Summary
This trial will test whether adding ertugliflozin, metolazone or placebo to intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy can improve heart failure signs and symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 291 Patients • NCT02226003Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a heart transplant or have serious heart valve disease.Your kidney function is very low, with an eGFR of 30 mL/min/1.73 m2 or less.I have major issues controlling my bladder.I have had many UTIs or a severe infection in my urinary tract.I have been taking a strong water pill daily for at least a month.My hemoglobin level is below 8g/dL.I am currently using or plan to start kidney replacement therapy this hospital stay.I am currently using or have recently used a water pill like hydrochlorothiazide.I have been diagnosed with acute heart failure and show signs of fluid buildup.I have a history of severe diabetes issues in the last 3 months.My doctor thinks I need and can handle treatment to remove a lot of fluid from my body.
- Group 1: Metolazone
- Group 2: Ertugliflozin
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedential experiments involving Ertugliflozin?
"Currently, there are 9 trials analyzing the efficacy of Ertugliflozin. 4 of those experiments have reached Phase 3. Although most studies take place in Cleveland Ohio, a total of 223 medical centres across the nation are performing research on this drug."
Has a similar research endeavor been conducted prior to this?
"Ertugliflozin has been subjected to clinical testing since 2019 and the initial trial was sponsored by MSD Korea Ltd.. This drug received Phase 3 approval after a study of 120 patients, which is now followed up with 9 active trials taking place in 137 cities across 26 nations."
What is the upper limit for enrollment in this clinical experiment?
"Affirmative. According to the data on clinicaltrials.gov, this medical trial is presently recruiting patients after being first published on March 10th 2021 and newly updated May 10th 2022. The investigation requires 90 participants from one center of care."
Are there any safety risks associated with Ertugliflozin consumption?
"The safety of Ertugliflozin scored a 2 on our team's rating scale due to the presence of Phase 2 data that is suggestive of its security, but no evidence demonstrating therapeutic efficacy."
Is enrolling now open for this clinical trial?
"Indeed, this clinical trial is still recruiting patients. It was initially made available to the public on March 10th 2021 and has had a few updates since then; most recently amended on May 10th 2022."
To what end is Ertugliflozin frequently employed?
"Ertugliflozin is generally prescribed for hypertensive disease, but has been known to reduce swelling of the extremities and improve exercise tolerance in patients with congestive heart failure."
Share this study with friends
Copy Link
Messenger